Payment overview · 2025
General Payments
$1,287.99
68 reported records · 19 companies
Healthcare provider profile · identity verified
April Gatson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LONGVIEW, TX · NPI 1649275470
Verified facts
What the public records show
CMS Open Payments records show April Gatson, M.D. received $1,287.99 in general payments during 2025 across 68 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SEROQUEL as an associated drug or biological on 59 records involving 53 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Seroquel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.03 | 15.6% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $175.42 | 13.6% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.78 | 11.6% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.38 | 5.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.58 | 5.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.09 | 5.5% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $64.94 | 5.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.71 | 4.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.94 | 4.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.76 | 4.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.85 | 4.0% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $51.27 | 4.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $46.02 | 3.6% | 2 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $43.44 | 3.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $27.20 | 2.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $23.98 | 1.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $23.68 | 1.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.72 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.20 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,287.99 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $175.42 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $173.89 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $149.78 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $136.67 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.38 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $76.38 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.58 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $71.09 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $64.94 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.94 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.94 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.76 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $51.85 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $51.27 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $46.02 | 2 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.75 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $12.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 69 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 92 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 116 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 297 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
92 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SEROQUEL open payments reported associated product |
CMS Open Payments — General Payments 59 supporting records · 53 recipient NPIs · example record 1241586771 |
Seroquel · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
80 | 23 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
116 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
297 | 54 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1230 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 717 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 662 | 173 |
| Pantoprazole Sodium | Pantoprazole Sodium | 517 | 123 |
| Potassium Chloride | Potassium Chloride | 448 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 429 | 107 |
| Gabapentin | Gabapentin | 407 | 100 |
| Clonazepam | Clonazepam | 354 | 64 |
| Tramadol Hcl | Tramadol Hcl | 352 | 63 |
| Azithromycin | Azithromycin | 328 | 176 |
| Lisinopril | Lisinopril | 313 | 88 |
| Ozempic | Semaglutide | 297 | 54 |
| Furosemide | Furosemide | 291 | 92 |
| Metformin Hcl | Metformin Hcl | 279 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 271 | 69 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 240 | 52 |
| Pregabalin | Pregabalin | 222 | 44 |
| Meloxicam | Meloxicam | 212 | 53 |
| Glimepiride | Glimepiride | 205 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 201 | 56 |
| Jardiance | Empagliflozin | 197 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 49 |
| Carvedilol | Carvedilol | 191 | 52 |
| Alprazolam | Alprazolam | 189 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 188 | 56 |
| Trazodone Hcl | Trazodone Hcl | 179 | 42 |
| Prednisone | Prednisone | 178 | 54 |
| Losartan Potassium | Losartan Potassium | 170 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 168 | 29 |
| Omeprazole | Omeprazole | 166 | 35 |
| Amoxicillin | Amoxicillin | 164 | 99 |
| Sertraline Hcl | Sertraline Hcl | 160 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 153 | 38 |
| Montelukast Sodium | Montelukast Sodium | 148 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 140 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 138 | 29 |
| Fluconazole | Fluconazole | 133 | 43 |
| Simvastatin | Simvastatin | 127 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 34 |
| Valsartan | Valsartan | 120 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 32 |
| Ibuprofen | Ibuprofen | 118 | 28 |
| Mounjaro | Tirzepatide | 116 | 21 |
| Clonidine Hcl | Clonidine Hcl | 114 | 38 |
| Baclofen | Baclofen | 112 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 32 |
| Allopurinol | Allopurinol | 104 | 26 |
| Famotidine | Famotidine | 101 | 32 |
| Promethazine Hcl | Promethazine Hcl | 100 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 99 | 42 |
| Valacyclovir | Valacyclovir Hcl | 96 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 95 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 92 | 16 |
| Farxiga | Dapagliflozin Propanediol | 92 | 24 |
| Bupropion Xl | Bupropion Hcl | 91 | 18 |
| Diazepam | Diazepam | 91 | 11 |
| Linzess | Linaclotide | 90 | 21 |
| Mirtazapine | Mirtazapine | 90 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 18 |
| Methylprednisolone | Methylprednisolone | 85 | 68 |
| Olanzapine | Olanzapine | 84 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 80 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 79 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 40 |
| Methocarbamol | Methocarbamol | 77 | 22 |
| Ezetimibe | Ezetimibe | 76 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 74 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 23 |
| Myrbetriq | Mirabegron | 71 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 71 | 18 |
| Estradiol | Estradiol | 70 | 16 |
| Eliquis | Apixaban | 69 | 14 |
| Atenolol | Atenolol | 68 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 14 |
| Spironolactone | Spironolactone | 68 | 20 |
| Donepezil Hcl | Donepezil Hcl | 66 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 45 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 40 |
| Torsemide | Torsemide | 63 | 20 |
| Cephalexin | Cephalexin | 62 | 46 |
| Lorazepam | Lorazepam | 62 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | suppressed |
| Nifedipine Er | Nifedipine | 58 | 13 |
| Benazepril Hcl | Benazepril Hcl | 56 | 12 |
| Buspirone Hcl | Buspirone Hcl | 55 | 15 |
| Temazepam | Temazepam | 55 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Ondansetron Odt | Ondansetron | 53 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 52 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Topiramate | Topiramate | 50 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 49 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 19 |
| Nystatin | Nystatin | 47 | 20 |
| Clindamycin Phosphate | Clindamycin Phosphate | 46 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 46 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 12 |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 11 |
| Mupirocin | Mupirocin | 42 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Naproxen | Naproxen | 41 | 11 |
| Sucralfate | Sucralfate | 40 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 11 |
| Levetiracetam | Levetiracetam | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 36 | 13 |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Lactulose | Lactulose | 35 | 12 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Bystolic | Nebivolol Hcl | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 11 |
| Finasteride | Finasteride | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 16 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Ethosuximide | Ethosuximide | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Seroquel | Quetiapine Fumarate | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,287.99 · 68 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, ELIQUIS, FARXIGA, GEMTESA, IBSRELA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, Quviviq, RELISTOR, REPATHA, Rybelsus, SPRAVATO, Symbravo, TONMYA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, VYEPTI, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error